Lupus & antiphospholipid syndrome
Real-world oral glucocorticoid use in SLE: a nation-wide population-based study using the French medico-administrative (SNDS) claim database
Authors' conclusion
In total, 48.2% of French patients with SLE were treated with OCS in 2019, including 12.4% at a mean dose >5 mg/day, with an increased risk of OCS complications and a limited use of antimalarials, immunosuppressants or biologics.
Study context
- Population
- Prevalent patients with SLE identified in the French national health insurance claims database (SNDS) in 201986.3% women
- Participants
- 31,852 patients
- Outcome
- OCS use and mean daily OCS dose (prednisone equivalent)
- Follow-up
- 2019
Methodological detailsnationwide, population-based, claims database
- Nationwide
- Population-based
- Claims database
Main finding
As reported in the abstract
Treated with OCS
48.3%
Mean daily OCS dose ≤5 mg/day
35.9%
Mean daily OCS dose >5 to <7.5 mg/day
6.4%
Mean daily OCS dose ≥7.5 mg/day
6.0%
Observational data: associations, not effects.
Further findings
Use of other SLE treatments by OCS dose
- Significantly increased in patients with higher OCS doses
- P < 0.0001
No antimalarial, immunosuppressant or biologic in patients on OCS >5 mg/day
- Not treated with antimalarial, immunosuppressant or biologic
- 13.6%
Safety
Potential OCS complications (CVD, infections, osteoporosis)
- Significantly increased in patients receiving >5 mg OCS/day
- P < 0.0001, for all
Original publication
Real-world oral glucocorticoid use in SLE: a nation-wide population-based study using the French medico-administrative (SNDS) claim database. Lupus Sci Med. Published 18 February 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →